▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2976 by analyst upside · 2026-09-27
ABT
Abbott Laboratories
Healthcare · Market Cap $175B · P/E 32.8x
ANALYST PRICE TARGET
+18.7%
implied upside to consensus target
Current Price $101.29
Consensus Target $120.26
Bull Target $135.0
Bear Target $103.0
Analysts Covering 25
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
17
Hold
5
Sell
0
52-Week Low $81.97
52-Week High $135.45
YTD Return -16.9%
FUNDAMENTALS
Market Cap $175B
P/E Ratio (TTM) 32.8x
Forward P/E 16.7x
EPS (TTM) $3.09
PEG Ratio 1.86
Dividend Yield 2.49%
Revenue (TTM) $46.6B
Profit Margin 11.6%
52-WEEK RANGE
52-Week Low $81.97
52-Week High $135.45
Current Price $101.29
Bear Target $103.0
Bull Target $135.0
● Now $101.29 ● Target $120.26
TRADING DATA
Avg Volume 9.9M
YTD Return -16.9%
Analyst Count 25
Consensus Buy
Upside to Target +18.7%
Last Updated 2026-09-27

ANALYST SUMMARY

Abbott Laboratories (ABT) is currently trading at $101.29 with a Wall Street consensus price target of $120.26, implying potential upside of 18.7% over the next 12 months. 25 analysts currently cover ABT, with a consensus rating of Buy - 81% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $135.0, while the most cautious has a target of $103.0.

ABT operates in the Healthcare sector with a market capitalisation of $175B. The stock is down 16.9% year-to-date and is currently trading near the lower end of its 52-week range of $81.97 – $135.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ABT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen reit
Buy → Buy 2026-09-08 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-08-25 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-08-21 Building track record
Citigroup - Reiterated
Buy → Buy 2026-08-14 Building track record
Wolfe Research ↑ Upgrade
Peer Perform → Outperform 2026-08-13 Building track record
UBS - Reiterated
Buy → Buy 2026-07-28 33% win rate (6 calls)
Citigroup - Reiterated
Buy → Buy 2026-07-17 Building track record
Piper Sandler reit
Overweight → Overweight 2026-07-17 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
71
out of 100
Coverage depth
25/30
Consensus clarity
24/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →